Compile Data Set for Download or QSAR
Report error Found 820 Enz. Inhib. hit(s) with Target = 'Proto-oncogene tyrosine-protein kinase receptor Ret [V804L]'
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716172(US12209085, Example 215)
Affinity DataIC50: 0.0600nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716174(US12209085, Example 214)
Affinity DataIC50: 0.100nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716171(US12209085, Example 4)
Affinity DataIC50: 0.200nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716173(US12209085, Example 194)
Affinity DataIC50: 0.230nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311622(Ex. Cpd. 59 | US10807986, Example 59 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311634(Ex. Cpd. 86 | US10807986, Example 86 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311639(Ex. Cpd. 91 | US10807986, Example 91 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311643(Ex. Cpd. 95 | US10807986, Example 95 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311651(Ex. Cpd. 103 | US10807986, Example 103 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311699(Ex. Cpd. 151 | US10807986, Example 151 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311700(Ex. Cpd. 152 | US10807986, Example 152 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311705(Ex. Cpd. 157 | US10807986, Example 157 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311717(Ex. Cpd. 169 | US10807986, Example 169 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311622(Ex. Cpd. 59 | US10807986, Example 59 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311634(Ex. Cpd. 86 | US10807986, Example 86 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311639(Ex. Cpd. 91 | US10807986, Example 91 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311643(Ex. Cpd. 95 | US10807986, Example 95 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311651(Ex. Cpd. 103 | US10807986, Example 103 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311699(Ex. Cpd. 151 | US10807986, Example 151 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311700(Ex. Cpd. 152 | US10807986, Example 152 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311705(Ex. Cpd. 157 | US10807986, Example 157 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311717(Ex. Cpd. 169 | US10807986, Example 169 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311699(Ex. Cpd. 151 | US10807986, Example 151 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716170(US12209085, Example 3)
Affinity DataIC50: 0.300nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311636(Ex. Cpd. 88 | US10807986, Example 88 | US11046696,...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311652(Ex. Cpd. 104 | US10807986, Example 104 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311653(Ex. Cpd. 105 | US10807986, Example 105 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311723(Ex. Cpd. 175 | US10807986, Example 175 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311636(Ex. Cpd. 88 | US10807986, Example 88 | US11046696,...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311652(Ex. Cpd. 104 | US10807986, Example 104 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311653(Ex. Cpd. 105 | US10807986, Example 105 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311723(Ex. Cpd. 175 | US10807986, Example 175 | US1104669...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311660(Ex. Cpd. 112 | US10807986, Example 112)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311679(Ex. Cpd. 131 | US10807986, Example 131 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311703(Ex. Cpd. 155 | US10807986, Example 155 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311704(Ex. Cpd. 156 | US10807986, Example 156 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311707(Ex. Cpd. 159 | US10807986, Example 159 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311660(Ex. Cpd. 112 | US10807986, Example 112)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311679(Ex. Cpd. 131 | US10807986, Example 131 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311703(Ex. Cpd. 155 | US10807986, Example 155 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311704(Ex. Cpd. 156 | US10807986, Example 156 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311707(Ex. Cpd. 159 | US10807986, Example 159 | US1104669...)
Affinity DataIC50: 0.5nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311635(Ex. Cpd. 87 | US10807986, Example 87 | US11046696,...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311637(Ex. Cpd. 89)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311673(Ex. Cpd. 125 | US10807986, Example 125 | US1104669...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311691(Ex. Cpd. 143 | US10807986, Example 143 | US1104669...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311708(Ex. Cpd. 160 | US10807986, Example 160 | US1104669...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311741(Ex. Cpd. 193 | US10807986, Example 193 | US1104669...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM311635(Ex. Cpd. 87 | US10807986, Example 87 | US11046696,...)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM469423(US10807986, Example 89 | US11046696, Compound 89)
Affinity DataIC50: 0.600nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 820 total ) | Next | Last >>
Jump to: